Twenty-two molecular diagnostic laboratories from 14 countries participated in a consortium study to estimate the impact of Factor Vlll gene inversions in severe hemophilia A. A total of 2,093 patients with severe hemophilia A were studied; of those, 740 (35%) had a type 1 (distal) factor Vi11 inversion, and 140 (7%) showed a type 2 (proximal) inversion. In 25 cases, the molecular analysis showed additional abnormal or polymorphic patterns. Ninety-eight percent of 532 mothers of patients with inversions were carriers of the abnormal factor Vlll gene; when only mothers of nonfamilial cases were studied, 9 de novo inversions in maternal germ EMOPHILIA A, ONE OF THE most common coagulation disorders with an incidence of about 1 in 5,000 to 10, OOO males, is caused by mutations in the gene for coagulation factor VIII.' This gene was cloned almost a decade agoz 
and many mutations have been ~haracterized.~-~ Most of the mutations are private, ie, they have been found in one or only a few unrelated families. Recently, a common inversion of factor VlII gene was identified in many unrelated patients with severe hemophilia A.',' The inversion is mediated by the presence of three copies of a particular DNA sequence (termed sequence A)'"'; one copy is located within intron 22 of the factor VIII gene' and the other two are 4 0 0 kb telomeric to the first.'"'3 Unequal crossing-over between two of these sequences results in inversion of a portion of the factor WI gene (exons 1 to 22) so that no intact factor VTII protein is produced. Cross-over between the most distal sequence A and its IVS22 homolog results in a type l inversion, apparently the most common inversional e~ent.7.'~ Cross-over between the proximal extragenic sequence A and its NS22 homolog results in a type 2 inversion. Both of these inversions can easily be diagnosed by Southern blot analysis using a probe from the IVS22.7 It appears that there is also a polymorphism of the A sequences that lie outside of the factor VIII gene, as some individuals have more than two copies of the extragenic sequence A.14 The Southern blot diagnostic patterns of inversions in these patients are different from those of types 1 and 2, termed here types 3A and 3B (Fig 1) . In a recent study using DNA polymorphism analysis to determine the origin of de novo inversions, the origin was almost always ~aternal.'~ The same study concluded that almost all mothers of patients with severe hemophilia A that was caused by factor Wr inversion were carriers of the in~ersion.'~ To determine the frequency of factor VI11 inversions in populations of severe hemophilia A patients, we collected data from a considerable number of hemophilia or molecular genetic diagnostic laboratories; this paper describes the results of these consortium DNA diagnostic studies for factor VI11 inversion mutations in hemophilia A.
MATERIALS AND METHODS
Each investigator contributed data to the first author's laboratory via a data submission questionnaire. Included were the number of 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 8.a ~0 0 9 0 0~9 9 9 9 9 9 9 9 9 9 9 9 9 9 ' 9 E P ._ 
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Cl ? ? For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Types of inversions of factor Vlll gene in severe hemophilia A unrelated patients with severe hemophilia A (factor VI11 activity less than I% of normal) studied by Southern blotting, the number of patients with each type of inversion, whether any inversion patient presented a mildhoderate phenotype, the number of mothers of inversion factor VI11 patients who were carriers either by pedigree or Southern blot analysis, the number of cases in which the origin of a de novo mutation was found, and the number of patients with severe hemophilia A with or without inversions that have developed factor VI11 inhibitors (antifactor VI11 antibodies). The diagnosis of the inversions in all laboratories was performed using Southern blot analysis as described.' Genomic DNA from patients with hemophilia A and members of their families was digested with Bcl I, the DNA fragments were electrophoresed on 0.7% agarose gels for 24 hours at SO V and transferred to nitrocellulose or nylon membranes. The membranes were probed with the 0.9-kb EcoRUSsr I fragment from plasmid p482.6' (American Type Culture Collection [ATCC] catalogue no. 57203). Earlier versions of the results from several laboratories have been published or presented in RESULTS AND DISCUSSION the presence of a factor VIII inversion. Because some laboratories have also studied patients with mildmoderate hemophilia A, the total number of patient.. studied was 2,560. A total of 25 patients had Southern blot patterns that differed both from normal and from type 1 or type 2 inversions, representing 1% of patients with severe hemophilia A analyzed. Ten of the 25 rare patterns belong to the type 3A or 3B categories (5 and 5, respectively); in the remaining 15 cases, the molecular basis of the Southern blot results has not yet been elucidated. These 15 cases may represent polymorphic (normal) variants or deletionshearrangements that involve intron 22 of the factor VI11 gene.
Results were also provided on the number of carrier mothers of patients with factor VI11 inversion severe hemophilia A ( Table 2 ). Based on family history and/or Southern blot analysis, 523 of 532 (98%) mothers were carriers of the inversion. This result confirms the earlier observation14 that almost all mothers of patients with severe hemophilia A that was caused by factor VIII inversions are carriers of the abnormal factor VI11 gene. A total of 255 of the 520 mothers were members of pedigrees with positive family history of hemophilia A, and therefore, the mothers were obligate carriers. There were 225 cases of inversion hemophilia A without family history in which the mothers were tested for carrier status by Southern blot analysis. In the 225 mothers, 216 (96%) were carriers of the factor VI11 inversions (Table 2) . Therefore, it seems that in sporadic cases of hemophilia A, there is 1 new mutation in the mother's germ cells (a mother who is not a carrier) in every 25 cases. The data on the origin of de novo factor VI11 inversions from the laboratory of group 14 in Malmo, Sweden, differ from these of all the other datasets.
The inversion originated in 4 of 14 mothers of patients with sporadic, severe hemophilia A with factor VI11 inversion. These data have been carefully checked on a second sample from the respective families.
The origin of certain de novo inversions of factor VI11 in the grandparental generation has been studied by Southern blotting and by analysis of DNA polymorphisms within or near the factor VI11 gene. The data collected on the origin of inversion mutations do not represent a thorough study of all cases; it is rather an opportunistic study based on the availability of DNA samples from the necessary family members. The de novo factor VI11 inversion originated in the male germ cells (maternal grandfather) of 69 cases and in the female germ cells of one case (maternal grandmother). These results include the data of Rossiter et all4 of 20 cases of grandparental origin. The grandmaternal origin from group 4 was obtained using an extragenic polymorphic marker (DXS52) for which the error rate in this determination is 1% to 5%. These data also concur with the earlier conclusion that the overwhelming majority of de novo mutations occur in male germ ~el1s.l~ Because the mean paternal age was not advanced in the study of Rossiter et al,I4 the hypothesis is that most de novo inversions occur in male meiosis.
The presence of inhibitors in patients with severe hemophilia A with or without inversions is also reported by the majority of the groups. The inhibitor titres varied widely among the groups. The frequency of inhibitors in the two categories of patients also varied widely among the different groups (Table 3) . A total of 130 patients of 642 studied (20%) with factor VIII inversions had developed inhibitors. Similarly, 131 patients of 821 studied (16%) with severe hemophilia A without factor VI11 inversions had developed inhibitors. The difference is marginally statistically significant (x2 = 4.53; df = 1; P = .033). The odds ratio for developing inhibitors in severe hemophilia A according to the presence or absence of factor VI11 inversions is 1.34 (95% confidence interval, 1.02 to 1.75). Therefore, we con- clude that the presence of factor VI11 gene inversion is not a major predisposing factor for the development of inhibitors.
The results presented here suffer from the limitations of studies based on questionnaires. The Southern blot analyses were performed in different laboratories with slightly different methodologies; no exchange of samples was done to perform interlaboratory quality assessment. In addition, in the data reported on inhibitors, no attempt was made to distinguish high versus low titer, or transient versus longterm inhibitors.
In summary, the results from the analysis of 2,093 severe hemophilia A patients in the consortium study of factor WI inversions indicate that (1) the type 1 inversion accounts for 35% and the type 2 inversion accounts for 7% of cases with severe hemophilia A , (2) in about 1% of cases of severe hemophilia A, rare Southern blot patterns are found (types 3A and 3B and other variants); (3) because of inversion, =98% of mothers of severe hemophilia A patients are carriers of the mutant factor VIII gene and, among mothers of sporadic cases, the frequency of carriers is 96%; (4) the majority of the de novo inversion mutation occurs in male germ cells; and (5) the presence of factor VIII inversions is not a major predisposing factor for the development of factor VIII inhibitors.
